Trial Profile
A Phase 1b Dose Escalation Trial of PSK/Placebo With Docetaxel to Treat Metastatic Castration-resistant Prostate Cancer
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 08 Apr 2022
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Polysaccharide K (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions
- 26 Oct 2015 Status changed from suspended to withdrawn prior to enrolment as per ClinicalTrials.gov record.
- 07 Oct 2013 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
- 13 May 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.